The effectiveness of androgen ablation in the management of advanced prostate cancer is
of limited duration, with the median length of response being only 18–24 months. The …

BACKGROUND Following androgen ablation therapy, the majority of prostate cancer
patients develop treatment resistance with a median time of 18–24 months to disease …

Since the pioneering studies of Huggins in 1941, it has been known that prostate cancer
cells, like certain normal epithelial cells, can chronically depend on a critical level of …

Prostate cancer is one of the major causes of cancer-related death in the western world.
Androgen-deprivation therapy (ADT) for the suppression of androgens binding to the …

Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland that is frequently
found in aging men. Androgens are essential for the development and differentiated function …

Androgen ablation is the primary treatment modality for patients with metastatic prostate
cancer; however, the role of androgen receptor signaling in prostate cancer development …

Prostate cancers require androgen for growth but progress to an androgen-independent
stage under the selective pressure of androgen ablation therapy. Here we describe a novel …

Since the pioneering studies of Huggins nearly 60 years ago, it has been known that
prostate cancer cells, like certain normal prostate epithelial cells, can chronically depend on …

The normal prostate and early-stage prostate cancers depend on androgens for growth and
survival, and androgen ablation therapy causes them to regress. Cancers that are not cured …

Prostate cancer carries significant morbidity and mortality, but its outcome is difficult to
predict in the individual. Androgen ablation delays progression in men, but hormone …